BI Asset Management Fondsmaeglerselskab A S Sells 29,206 Shares of DaVita Inc. $DVA

Key Points

• BI Asset Management Fondsmaeglerselskab A S has reduced its stake in DaVita Inc. by 22.1%, holding approximately $15.71 million in shares as of the latest quarter.
• DaVita's earnings per share (EPS) for the most recent quarter was reported at $2.95, exceeding the consensus estimate by $0.25.
• Wall Street analysts have shown mixed sentiments, with one upgrading DaVita to a "buy" rating while others have adjusted their target prices, setting an average target of $164.00.

BI Asset Management Fondsmaeglerselskab A S reduced its stake in DaVita Inc. (NYSE:DVA - Free Report) by 22.1% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 102,667 shares of the company's stock after selling 29,206 shares during the period. BI Asset Management Fondsmaeglerselskab A S owned about 0.13% of DaVita worth $15,705,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently modified their holdings of DVA. Iron Triangle Partners LP bought a new position in shares of DaVita during the fourth quarter valued at $38,946,000. GAMMA Investing LLC raised its holdings in DaVita by 14,695.8% during the 1st quarter. GAMMA Investing LLC now owns 234,809 shares of the company's stock worth $35,919,000 after purchasing an additional 233,222 shares during the last quarter. Northern Trust Corp raised its holdings in DaVita by 20.2% during the 1st quarter. Northern Trust Corp now owns 890,632 shares of the company's stock worth $136,240,000 after purchasing an additional 149,858 shares during the last quarter. Nuveen LLC bought a new position in DaVita during the 1st quarter worth approximately $20,218,000. Finally, Rovin Capital UT ADV bought a new position in DaVita during the 1st quarter worth approximately $18,442,000. Institutional investors own 90.12% of the company's stock.

DaVita Stock Down 1.4%

DVA stock traded down $1.9940 during midday trading on Monday, reaching $138.3660. 125,997 shares of the company's stock traded hands, compared to its average volume of 856,276. The company has a market cap of $9.89 billion, a price-to-earnings ratio of 13.60, a P/E/G ratio of 1.01 and a beta of 1.09. The firm's fifty day moving average price is $139.63 and its 200-day moving average price is $143.70. The company has a quick ratio of 1.34, a current ratio of 1.39 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 52 week low of $126.07 and a 52 week high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $2.95 EPS for the quarter, beating analysts' consensus estimates of $2.70 by $0.25. The business had revenue of $3.38 billion during the quarter, compared to analyst estimates of $3.36 billion. DaVita had a net margin of 6.35% and a return on equity of 369.39%. DaVita's quarterly revenue was up 6.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.00 EPS. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. As a group, sell-side analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Insider Buying and Selling at DaVita

In related news, insider James O. Hearty sold 2,351 shares of the firm's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total transaction of $352,650.00. Following the transaction, the insider directly owned 26,038 shares of the company's stock, valued at $3,905,700. This trade represents a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on DVA shares. Truist Financial set a $148.00 price target on shares of DaVita in a report on Friday, August 8th. Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a report on Friday. Finally, Barclays reduced their price target on shares of DaVita from $169.00 to $160.00 and set an "equal weight" rating for the company in a report on Thursday, August 7th. Three analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, DaVita currently has a consensus rating of "Hold" and an average price target of $164.00.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.